• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过协同胆汁酸调节释放mRNA疫苗在肝癌治疗中的潜力。

Unlocking mRNA Vaccine Potential in Liver Cancer Treatment via Synergistic Bile Acid Modulation.

作者信息

Wang Yuqian, Han Rui, Ling Changquan

机构信息

School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Department of Traditional Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200433, China.

出版信息

Vaccines (Basel). 2025 May 9;13(5):502. doi: 10.3390/vaccines13050502.

DOI:10.3390/vaccines13050502
PMID:40432113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12115901/
Abstract

This Letter to the Editor explores synergistic mechanisms enhancing mRNA cancer vaccine efficacy through bile acid metabolism modulation in liver cancer treatment. The latest evidence indicates that bile acids significantly impair T cell function within the liver cancer microenvironment, creating an immunosuppressive milieu that hampers anti-tumor responses. Modulating bile acid composition, particularly increasing ursodeoxycholic acid (UDCA), could reshape the tumor microenvironment (TME) to favor mRNA vaccine-induced T cell activity-a promising strategy to overcome current immunotherapy limitations in liver cancer.

摘要

这封致编辑的信探讨了在肝癌治疗中通过调节胆汁酸代谢增强mRNA癌症疫苗疗效的协同机制。最新证据表明,胆汁酸会显著损害肝癌微环境中的T细胞功能,营造出一种抑制抗肿瘤反应的免疫抑制环境。调节胆汁酸组成,特别是增加熊去氧胆酸(UDCA),可以重塑肿瘤微环境(TME),以利于mRNA疫苗诱导的T细胞活性——这是一种克服当前肝癌免疫治疗局限性的有前景的策略。

相似文献

1
Unlocking mRNA Vaccine Potential in Liver Cancer Treatment via Synergistic Bile Acid Modulation.通过协同胆汁酸调节释放mRNA疫苗在肝癌治疗中的潜力。
Vaccines (Basel). 2025 May 9;13(5):502. doi: 10.3390/vaccines13050502.
2
Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.熊去氧胆酸治疗后慢性肝病患者血清和尿液中硫酸化熊去氧胆酸增加。
J Gastroenterol Hepatol. 1996 Apr;11(4):385-90. doi: 10.1111/j.1440-1746.1996.tb01388.x.
3
Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.熊去氧胆酸治疗囊性纤维化相关肝病的效果
J Pediatr. 1990 Sep;117(3):482-9. doi: 10.1016/s0022-3476(05)81103-5.
4
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling.UDCA 和 norUDCA 在脂肪变性啮齿动物模型中的有益作用与 GPBAR1/FXR 信号的调节有关。
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Nov;1867(11):159218. doi: 10.1016/j.bbalip.2022.159218. Epub 2022 Aug 18.
5
Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans.长期服用辛伐他汀作为熊去氧胆酸辅助治疗的效果:对人体胆汁胆汁酸组成有协同作用,但对血清脂质无协同作用的证据。
Gut. 1999 Apr;44(4):552-6. doi: 10.1136/gut.44.4.552.
6
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.熊去氧胆酸在多囊肝病实验模型中抑制肝脏囊肿形成。
J Hepatol. 2015 Oct;63(4):952-61. doi: 10.1016/j.jhep.2015.05.023. Epub 2015 Jun 1.
7
Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition.熊去氧胆酸治疗可改善胆汁酸疏水性:基于具有类似人胆汁酸组成的小鼠模型的研究。作用具有性别、年龄和器官依赖性。
PLoS One. 2022 Jul 12;17(7):e0271308. doi: 10.1371/journal.pone.0271308. eCollection 2022.
8
Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.原发性胆汁性肝硬化中的胆酸和熊去氧胆酸治疗。胆汁酸模式的变化及其与肝功能的相关性。
Eur J Clin Pharmacol. 1993;45(3):221-5. doi: 10.1007/BF00315387.
9
A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis.高剂量熊去氧胆酸通过重塑肠道微生物群和胆汁酸谱缓解非酒精性脂肪性肝炎小鼠模型的肝脏炎症。
Biomed Pharmacother. 2024 May;174:116617. doi: 10.1016/j.biopha.2024.116617. Epub 2024 Apr 20.
10
Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon.熊去氧胆酸和石胆酸在结肠中发挥抗炎作用。
Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1;312(6):G550-G558. doi: 10.1152/ajpgi.00256.2016. Epub 2017 Mar 30.

本文引用的文献

1
Clinical advances of mRNA vaccines for cancer immunotherapy.用于癌症免疫治疗的mRNA疫苗的临床进展。
Med. 2025 Jan 10;6(1):100562. doi: 10.1016/j.medj.2024.11.015.
2
Bile acid synthesis impedes tumor-specific T cell responses during liver cancer.胆汁酸合成会阻碍肝癌发生过程中的肿瘤特异性T细胞反应。
Science. 2025 Jan 10;387(6730):192-201. doi: 10.1126/science.adl4100. Epub 2025 Jan 9.
3
Cancer mRNA vaccines: clinical advances and future opportunities.癌症 mRNA 疫苗:临床进展和未来机遇。
Nat Rev Clin Oncol. 2024 Jul;21(7):489-500. doi: 10.1038/s41571-024-00902-1. Epub 2024 May 17.
4
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.个体化新抗原疗法mRNA-4157(V940)联合帕博利珠单抗与帕博利珠单抗单药治疗可切除黑色素瘤(KEYNOTE-942):一项随机2b期研究
Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18.
5
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8 T cells to boost anti-PD-1 therapy.载有肿瘤抗原和瑞喹莫德的细胞微粒重编程肿瘤相关巨噬细胞,并促进类干细胞 CD8 T 细胞,从而增强抗 PD-1 治疗效果。
Nat Commun. 2023 Sep 13;14(1):5653. doi: 10.1038/s41467-023-41438-9.
6
Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects.利用 mRNA-脂质纳米颗粒靶向癌症:关键考虑因素和未来前景。
Nat Rev Clin Oncol. 2023 Nov;20(11):739-754. doi: 10.1038/s41571-023-00811-9. Epub 2023 Aug 16.
7
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy.脂质纳米颗粒 (LNP) 可实现癌症治疗的 mRNA 递送。
Adv Mater. 2023 Dec;35(51):e2303261. doi: 10.1002/adma.202303261. Epub 2023 Nov 1.
8
mRNA Vaccine Slows Melanoma Recurrence.mRNA 疫苗减缓黑色素瘤复发。
Cancer Discov. 2023 Jun 2;13(6):1278. doi: 10.1158/2159-8290.CD-NB2023-0028.
9
Immune checkpoint therapy-current perspectives and future directions.免疫检查点治疗——现状与未来方向。
Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006.
10
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.mRNA 疫苗:癌症免疫治疗新时代的曙光。
Front Immunol. 2022 Jun 2;13:887125. doi: 10.3389/fimmu.2022.887125. eCollection 2022.